CN107686522A - 一种识别hla‑a2/sllmwitqc的单域抗体 - Google Patents

一种识别hla‑a2/sllmwitqc的单域抗体 Download PDF

Info

Publication number
CN107686522A
CN107686522A CN201611240366.1A CN201611240366A CN107686522A CN 107686522 A CN107686522 A CN 107686522A CN 201611240366 A CN201611240366 A CN 201611240366A CN 107686522 A CN107686522 A CN 107686522A
Authority
CN
China
Prior art keywords
single domain
seq
domain antibody
sllmwitqc
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201611240366.1A
Other languages
English (en)
Chinese (zh)
Inventor
吕丽慧
高斌
古明珠
刘莹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHENZHEN BEIKE BIO-TECHNOLOGY Co.,Ltd.
Original Assignee
Tianjin Tian Rui Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Tian Rui Biotechnology Co Ltd filed Critical Tianjin Tian Rui Biotechnology Co Ltd
Priority to CN201611240366.1A priority Critical patent/CN107686522A/zh
Priority to PCT/CN2017/118287 priority patent/WO2018121475A1/fr
Publication of CN107686522A publication Critical patent/CN107686522A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
CN201611240366.1A 2016-12-28 2016-12-28 一种识别hla‑a2/sllmwitqc的单域抗体 Pending CN107686522A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201611240366.1A CN107686522A (zh) 2016-12-28 2016-12-28 一种识别hla‑a2/sllmwitqc的单域抗体
PCT/CN2017/118287 WO2018121475A1 (fr) 2016-12-28 2017-12-25 Complexe de reconnaissance d'anticorps à domaine unique formé par une molécule hla-a2 et un peptide court sllmwitqc

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611240366.1A CN107686522A (zh) 2016-12-28 2016-12-28 一种识别hla‑a2/sllmwitqc的单域抗体

Publications (1)

Publication Number Publication Date
CN107686522A true CN107686522A (zh) 2018-02-13

Family

ID=61152304

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201611240366.1A Pending CN107686522A (zh) 2016-12-28 2016-12-28 一种识别hla‑a2/sllmwitqc的单域抗体

Country Status (2)

Country Link
CN (1) CN107686522A (fr)
WO (1) WO2018121475A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110407924A (zh) * 2019-07-24 2019-11-05 暨南大学 靶向cd133的结合蛋白及其应用
CN110872347A (zh) * 2018-08-30 2020-03-10 天津天锐生物科技有限公司 一种识别hla-a2分子与itdqvpfsv短肽形成的复合物的单域抗体

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053938A1 (fr) * 1998-04-17 1999-10-28 Ludwig Institute For Cancer Research Peptides isoles correspondant a des sequences d'acides amines de ny-eso-1 qui se lient a des molecules mhc de classe i et mhc de classe ii, et leurs utilisations
CN101001868A (zh) * 2004-06-17 2007-07-18 曼康公司 表位类似物
WO2010106431A2 (fr) * 2009-03-20 2010-09-23 Ludwig Institute For Cancer Research Ltd Anticorps anti-peptide ny-eso-1 de type récepteur des cellules t de haute affinité, procédés, et leurs utilisations
CN102120772A (zh) * 2010-01-08 2011-07-13 中国科学院微生物研究所 一种嵌合抗体及免疫细胞
WO2013105856A1 (fr) * 2012-01-13 2013-07-18 Apo-T B.V. Immunoglobulines restreintes à une cellule aberrante dotées d'une fraction toxique
US20160271292A1 (en) * 2013-11-11 2016-09-22 Georgia Tech Research Corporation Functionalized microgels with fibrin binding elements

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6992176B2 (en) * 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053938A1 (fr) * 1998-04-17 1999-10-28 Ludwig Institute For Cancer Research Peptides isoles correspondant a des sequences d'acides amines de ny-eso-1 qui se lient a des molecules mhc de classe i et mhc de classe ii, et leurs utilisations
CN1303300A (zh) * 1998-04-17 2001-07-11 路德维格癌症研究院 分离的结合mhci类和mhcii类分子的同ny－eso－1的氨基酸序列相关的肽及其应用
CN101001868A (zh) * 2004-06-17 2007-07-18 曼康公司 表位类似物
WO2010106431A2 (fr) * 2009-03-20 2010-09-23 Ludwig Institute For Cancer Research Ltd Anticorps anti-peptide ny-eso-1 de type récepteur des cellules t de haute affinité, procédés, et leurs utilisations
CN102120772A (zh) * 2010-01-08 2011-07-13 中国科学院微生物研究所 一种嵌合抗体及免疫细胞
WO2013105856A1 (fr) * 2012-01-13 2013-07-18 Apo-T B.V. Immunoglobulines restreintes à une cellule aberrante dotées d'une fraction toxique
US20160271292A1 (en) * 2013-11-11 2016-09-22 Georgia Tech Research Corporation Functionalized microgels with fibrin binding elements

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HELD,G等: "Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments", 《EUR J IMMUNOL》 *
HELD,G等: "MHC/Peptide-Specific Interaction of the Humoral Immune System: A New Category of Antibodies", 《JOURNAL OR IMMUNOLOGY》 *
吕丽慧等: "特异性识别胞内NY-ESO-1抗原的抗体", 《第十二届全国免疫学学术大会摘要汇编中国免疫学会会议论文集》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110872347A (zh) * 2018-08-30 2020-03-10 天津天锐生物科技有限公司 一种识别hla-a2分子与itdqvpfsv短肽形成的复合物的单域抗体
CN110407924A (zh) * 2019-07-24 2019-11-05 暨南大学 靶向cd133的结合蛋白及其应用
CN110407924B (zh) * 2019-07-24 2021-12-21 暨南大学 靶向cd133的结合蛋白及其应用

Also Published As

Publication number Publication date
WO2018121475A1 (fr) 2018-07-05

Similar Documents

Publication Publication Date Title
JP2018520675A (ja) ジユビキチン変異タンパク質をベースとした新規結合タンパク質及びその生成方法
CN107674122A (zh) 一种识别人血清白蛋白的单域抗体
CN111848798B (zh) 可结合bcma的纳米抗体及其应用
WO2020125120A1 (fr) Procédé de construction d'une bibliothèque d'anticorps et son application
CN111378043B (zh) 一种具有中和作用的人鼠嵌合抗Siglec-15全分子IgG及其制备方法和应用
US9511342B2 (en) Antibody preparation method, and antibody and antibody library thus prepared
Stern et al. Geometry and expression enhance enrichment of functional yeast‐displayed ligands via cell panning
JP6843262B2 (ja) 改良型抗ｖｅｇｆｒ−２モノクローナル抗体
CN103709251B (zh) 全人源抗cd26抗体及其应用
CN108084265B (zh) 特异性结合人的5t4抗原的全人源单域抗体及其应用
WO2011057435A1 (fr) Anticorps anti-récepteur de facteur de croissance épidermique et utilisations de ceux-ci
CN111825767B (zh) 一种人表皮生长因子受体2的单域抗体、检测试剂盒及其应用
CN103641917B (zh) 抗cd26抗体及其应用
CN111234020A (zh) 一种bcma结合蛋白及其制备方法和应用
CN115010811A (zh) 可特异性结合EpCAM的单域抗体及其应用
CN112028997A (zh) 抗ceacam5纳米抗体
CN117050165A (zh) 一种靶向猴痘病毒的抗体、其抗原结合片段及其用途
CN107686522A (zh) 一种识别hla‑a2/sllmwitqc的单域抗体
CN108530538B (zh) EpCAM单域抗体E6
WO2022134276A1 (fr) Anticorps anti-ostéopontine humain et son utilisation
CN107698681B (zh) 一种识别hla-a2/rmfpnapyl的单域抗体
WO2011057437A1 (fr) Anticorps contre le récepteur du facteur de croissance épidémique, gènes codants pour celui-ci et ses utilisations
CN108586614B (zh) EpCAM单域抗体D7
KR101473328B1 (ko) 사이토케라틴１７―특이적인 인간항체
WO2023273595A1 (fr) Anticorps se liant à trop2, anticorps bispécifique ciblant trop2 et cd3, procédés de préparation associés et utilisations correspondantes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210324

Address after: 16 / F, Beike building, 59 Gaoxin South 9th Road, Yuehai street, Nanshan District, Shenzhen, Guangdong 518000

Applicant after: SHENZHEN BEIKE BIO-TECHNOLOGY Co.,Ltd.

Address before: Room 201, 2 / F, building 19, West District, airport business park, No.76 Huanhe North Road, Tianjin Binhai New Area Free Trade Zone (Airport Economic Zone), 300300

Applicant before: TIMMUNE BIOTECH Inc.

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180213